Alzheimer's Disease
DNLIDenali TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for DNL628 (Tau-Targeting Oligonucleotide) in Alzheimer's Disease. The expected timing is based on the latest available company guidance and may change.
02/26/26:- Phase 1b Alzheimer's study CTA approved for DNL628; start-up activities underway. 05/07/26:- First patient dosed in Ph1b Alzheimer's study in March 2026; data expected in H1 2027. 08/06/26:- Ph1b biomarker data remain expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.